TroyGould Represents Kindred Biosciences, Inc. in $46 Million Public Offering
TroyGould PC represented Kindred Biosciences, Inc. in its underwritten public offering of 4,847,250 shares of common stock, at $9.50 per share. The offering closed on January 23, 2019, with gross proceeds to KindredBio of approximately $46 million. KindredBio is a Nasdaq listed commercial-stage biopharmaceutical company focused on saving and improving the lives of pets.
Barclays Capital Inc. and Stifel acted as joint book-running managers.